IL319242A - Estrogen Receptor Blocker Dosage Regimen - Google Patents

Estrogen Receptor Blocker Dosage Regimen

Info

Publication number
IL319242A
IL319242A IL319242A IL31924225A IL319242A IL 319242 A IL319242 A IL 319242A IL 319242 A IL319242 A IL 319242A IL 31924225 A IL31924225 A IL 31924225A IL 319242 A IL319242 A IL 319242A
Authority
IL
Israel
Prior art keywords
estrogen receptor
dosage regimens
receptor degraders
degraders
regimens
Prior art date
Application number
IL319242A
Other languages
English (en)
Hebrew (he)
Inventor
Ronald Peck
Sheryl Maxine Gough
John J Flanagan
Sibyl Anderson
Ian Charles Anthony Taylor
Julia Perkins Smith
Weiwei Tan
Original Assignee
Arvinas Operations Inc
Pfizer
Ronald Peck
Sheryl Maxine Gough
John J Flanagan
Sibyl Anderson
Ian Charles Anthony Taylor
Julia Perkins Smith
Weiwei Tan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvinas Operations Inc, Pfizer, Ronald Peck, Sheryl Maxine Gough, John J Flanagan, Sibyl Anderson, Ian Charles Anthony Taylor, Julia Perkins Smith, Weiwei Tan filed Critical Arvinas Operations Inc
Publication of IL319242A publication Critical patent/IL319242A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL319242A 2022-08-31 2023-08-30 Estrogen Receptor Blocker Dosage Regimen IL319242A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263402651P 2022-08-31 2022-08-31
US202363443892P 2023-02-07 2023-02-07
US202363454422P 2023-03-24 2023-03-24
US202363454485P 2023-03-24 2023-03-24
US202363508503P 2023-06-15 2023-06-15
PCT/US2023/031574 WO2024049926A1 (en) 2022-08-31 2023-08-30 Dosage regimens of estrogen receptor degraders

Publications (1)

Publication Number Publication Date
IL319242A true IL319242A (en) 2025-04-01

Family

ID=88192329

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319242A IL319242A (en) 2022-08-31 2023-08-30 Estrogen Receptor Blocker Dosage Regimen

Country Status (10)

Country Link
EP (1) EP4580631A1 (es)
JP (1) JP2025530742A (es)
KR (1) KR20250076543A (es)
CN (1) CN120112291A (es)
AU (1) AU2023336057A1 (es)
CA (1) CA3266061A1 (es)
IL (1) IL319242A (es)
MX (1) MX2025002284A (es)
TW (2) TW202539669A (es)
WO (1) WO2024049926A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021041348A1 (en) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
CN119258223A (zh) * 2023-07-06 2025-01-07 海创药业股份有限公司 一种降解雌激素受体的联合用药物及其用途
WO2026044127A1 (en) * 2024-08-22 2026-02-26 Arvinas Operations, Inc. Administration of cyp3a inhibitors in the treatment of cancer
WO2026128391A1 (en) * 2024-12-09 2026-06-18 Arvinas Operations, Inc. Combinations of vepdegestrant and cdk4/6 inhibitors for treating esr1-mutant breast cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
DE602004017474D1 (de) 2003-07-11 2008-12-11 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
KR20090052385A (ko) 2006-09-08 2009-05-25 화이자 프로덕츠 인크. 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온의합성
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
DK3431475T3 (da) 2013-02-21 2021-05-25 Pfizer Faste former af en selektiv CDK4/6-hæmmer
SI4197530T1 (sl) 2015-04-16 2026-03-31 Novartis Ag Tableta ribocikliba
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
WO2021041348A1 (en) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
IL303143A (en) * 2020-12-14 2023-07-01 Arvinas Operations Inc Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders

Also Published As

Publication number Publication date
CA3266061A1 (en) 2024-03-07
AU2023336057A1 (en) 2025-03-27
EP4580631A1 (en) 2025-07-09
TW202416991A (zh) 2024-05-01
WO2024049926A1 (en) 2024-03-07
CN120112291A (zh) 2025-06-06
TW202539669A (zh) 2025-10-16
KR20250076543A (ko) 2025-05-29
MX2025002284A (es) 2025-06-02
TWI866427B (zh) 2024-12-11
JP2025530742A (ja) 2025-09-17

Similar Documents

Publication Publication Date Title
CA3266061A1 (en) DOSING REGIMEN BASED ON ESTROGEN RECEPTOR DEGRADING AGENTS
GB2595776B (en) Therapeutic solid dosage forms
IL308389A (en) Dosing regimens for acubactadine
IL295598A (en) Selective estrogen receptor antagonists
PL4370116T3 (pl) Schematy dawkowania afikamtenu do leczenia obturacyjnej kardiomiopatii przerostowej
SG11202100145YA (en) Selective estrogen receptor degraders
ZA202201157B (en) Selective estrogen receptor degrader
IL320859A (en) Methods for treating breast cancer with selective estrogen receptor blockers (SERDs)
IL315886A (en) Dosing regimens for anti-CD19 agents and their uses
IL313886A (en) Processes for the preparation of selective compounds of estrogen receptors
CA3295229A1 (en) Solid oral dosage forms of estrogen receptor degraders
GB202004115D0 (en) Modified release formulations and dosage regimens
CA3274497A1 (en) Dosage forms of an estrogen receptor antagonist
IL315178A (en) Dosage regimen
IL304354A (en) Ridinilazole solid tablet dosage form
EP3932490A4 (en) ANTIPRURIC AGENT USING PAC1 RECEPTOR ANTAGONISTS
EP4310079A4 (en) ESTROGEN RECEPTOR ANTAGONIST
HK40108270A (zh) 依维替定的给药方案
LT3277278T (lt) Kombinuota vaisto forma mu opioidinio receptoriaus antagonisto ir opioidinio agento
CA3288633A1 (en) Advantageous human dosage regimens for administration of inx-315
GB2621351B (en) Metered dosage apparatus
IL325443A (en) Combination therapy for the relief of side effects caused by the use of estrogen receptor inhibitors
HK40087442A (en) Preparation of an selective estrogen receptor degrader
HK40105571A (zh) Parp7抑制剂的剂量方案
GB202209299D0 (en) Dosage regimen for antiviral therapy